Mr. Elad Bibi-Aviv reports
SEEGNAL INC. ANNOUNCES Q3 FILING EXEMPTION AND APPOINTMENT OF A SPECIAL COMMITTEE TO REVIEW STRATEGIC ALTERNATIVES
Seegnal Inc. has adopted semi-annual financial reporting. This news release is being filed pursuant to Coordinated Blanket Order 51-933 (Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers).
CBO 51-933 allows eligible venture issuers to voluntarily move from a quarterly to a semi-annual financial reporting framework. Seegnal's fiscal year ends on Dec. 31. Under the provisions of CBO 51-933, Seegnal will be exempt from the requirements to file its nine-month interim financial statements and associated management's discussion and analysis as it meets the eligibility criteria under CBO 51-933, which include being a venture issuer with annual revenues of less than $10-million and maintaining a clean 12-month continuous disclosure record. Accordingly, Seegnal will not be filing its interim financial statements for the nine-month period ended Sept. 30, 2026, and associated MD&A.
Seegnal will continue to file audited annual financial statements (due within 120 days of Dec. 31, 2026) and six-month interim financial reports (due next within 60 days of June 30, 2027). Seegnal remains committed to timely disclosure, and will continue to report all material changes and significant developments as required under National Instrument 51-102 (Continuous Disclosure Obligations).
Special committee
The company's board of directors has established a special committee of independent directors to lead the company's evaluation of strategic and financing alternatives.
The special committee is exploring a full range of options, which may include, but are not limited to, a merger, sale, related-party transaction or other alternative. To assist in its work, the special committee may engage professional advisers as it considers appropriate, including legal, financial and accounting advisers.
The board has not set a timetable for this evaluation process, nor has it made any decisions regarding any potential strategic transaction. There can be no assurance that this process will result in any transaction. The company does not intend to provide updates or make further comments regarding these matters unless and until it determines that additional disclosure is appropriate or required by law. Seegnal cautions that there are no guarantees that the evaluation processes will result in any particular outcome. The company will continue to operate its business as usual as it undertakes these evaluation processes.
About Seegnal Inc.
Seegnal is an innovative health care technology company dedicated to reducing medication-related harm where care begins. The company's software-as-a-service-based clinical decision support platform is designed to help clinicians prescribe with greater precision by integrating patient-specific data at the point of care, including medications, laboratory results, renal function, allergies, age and other relevant risk factors. By delivering more targeted, context-aware medication insights within existing clinical workflows, Seegnal aims to reduce alert fatigue, support safer prescribing and advance a more personalized standard of patient care. Seegnal's technology is deployed across health care settings and is used by approximately 15,000 clinicians in daily practice.
We seek Safe Harbor.
© 2026 Canjex Publishing Ltd. All rights reserved.